The Pharmacy Times® Retail Clinical Role section is a comprehensive resource for clinical news and expert insights on issues pertaining to retail, community, and independent pharmacists.
April 26th 2025
New research confirms hydroxyurea's long-term effectiveness in reducing hospital visits for children with sickle cell anemia, supporting its use as standard treatment.
Avella Selected by Pfizer to Distribute Ibrance
February 9th 2015Avella Specialty Pharmacy announced today that it has been selected by Pfizer as one of the limited groups of specialty pharmacies authorized to distribute the manufacturer's breakthrough breast cancer drug-Ibrance (palbociclib)-which has just received fast-tracked approval from the FDA.
Read More
In celebration of Heart Failure Awareness Week, the American Heart Association would like to recognize Amgen for their support of the AHA's Get With The Guidelines®-Heart Failure initiative. Amgen's support will help achieve the goal of improving care for heart failure by helping to educate physicians and patients about consistent adherence to the latest evidence-based treatment guidelines.
Read More
Pharmacists: Bill Would Expand Seniors' Access to Lower Drug Copays
February 9th 2015Seniors would have more convenient access to discounted or "preferred" copays for prescription drugs at their pharmacy of choice under new bipartisan legislation introduced recently and endorsed today by the National Community Pharmacists Association.
Read More
CDC: 1 in 5 Young Diabetics Lack Sufficient Care
February 9th 2015Although the American Diabetes Association recommends that adult patients with diagnosed diabetes visit a health care professional biannually to achieve and maintain glycemic control, a recent report from the National Center for Health Statistics in the US Centers for Disease Control and Prevention shows that 1 in 5 younger diabetics have not done so in the past 6 months.
Read More
Mylan Confirms First-to-File Patent Challenge Relating to NEXAVAR(R)
February 9th 2015Mylan Inc. today confirmed that it and its subsidiary Mylan Pharmaceuticals have been sued by Bayer Healthcare LLC, Bayer Healthcare Pharmaceuticals Inc., and Onyx Pharmaceuticals Inc., in connection with the filing of an Abbreviated New Drug Application with the U.S. Food and Drug Administration for Sorafenib Tablets, 200 mg. This product is the generic version of NEXAVAR®, which is indicated for the treatment of certain types of cancers including unresectable hepatocellular carcinoma and advanced renal cell carcinoma.
Read More
Pharmacy Development Services (PDS), the leading provider of business education for independent pharmacy owners, has announced the ten recipients of the 2015 PDS Conference Showcase of Success. For the past nine years, the Showcase of Success segment has been an integral part of the annual business growth conference as a way to demonstrate the opportunities for real results in the industry.
Read More
Pharmacy Times today announced a strategic collaboration with the Pharmacy Podcast Show to strengthen dialogue and spur innovation around key topics regarding the pharmacy profession, health care, and pharmacy business. Pharmacy Podcast creator and host Todd S. Eury will work with Pharmacy Times to create future content and episodes of the podcast that will be integrated into the blog section of the Pharmacy Times website.
Read More
Adverse Reactions to Methylphenidate ADHD Treatment Aren't Serious
February 8th 2015Although children with attention deficit hyperactivity disorder often experience decreased appetite and sleep disturbances during methylphenidate treatment, a study published in the Journal of Research in Pharmacy Practice indicates that those adverse drug reactions (ADRs) are mostly mild and not serious.
Read More
"Holes in the Herd" Linked to Measles Spread
February 7th 2015The current measles outbreak across 14 US states indicates that too few individuals are being vaccinated to prevent infections, according to Jason Gallagher, a clinical pharmacy specialist in infectious diseases at Temple University.
Read More